BALVERSA Adoption On The Rise: Meeting Unmet Needs In Advanced Urothelial Cancer | Delveinsight
BALVERSA (erdafitinib) has strong market potential in the FGFR-altered urothelial carcinoma space, particularly as a targeted therapy for patients wi ...